Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI346 in Relapsed/Refractory Multiple Myeloma
NCT05270928Phase 1Completed
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Apr 2022
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBI346 in multiple myeloma (MM), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Dose Limiting Toxicity at 21 days, Incidence and severity of adverse events at 2 years and 1 more. Started Apr 2022; status: completed.
02
Drugs
IBI346
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05270928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05270928.